Actavis Confirms Generic Multaq® Patent Challenge

[PR Newswire] – DUBLIN, Feb. 28, 2014 /PRNewswire/ — Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval … more

View todays social media effects on ACT

View the latest stocks trending across Twitter. Click to view dashboard

See who Actavis is hiring next, click here to view